Get started
AAA

ASCELIA PHARMA AB

No trades
See on Supercharts
Overview
Financials News Discussions Technicals Seasonals

ACE chart


Full chart

ACE upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪261.34 M‬ SEK
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.255 SEK
Net income (FY)
‪−109.29 M‬ SEK
Revenue (FY)
0.00 SEK
Shares float
‪90.74 M‬
Beta (1Y)
0.56

Employees


Employees (FY)
13
Change (1Y)
−11 −45.83%
Revenue / Employee (1Y)
0.00 SEK
Net income / Employee (1Y)
‪−829.75 K‬ SEK

About ASCELIA PHARMA AB


Sector
Health Technology
CEO
Magnus Olafsson Corfitzen
Headquarters
Malmö
Website
cmc-contrast.se
Founded
1999
ISIN
SE0010573113
FIGI
BBG00NF05BL9
Ascelia Pharma AB engages in the research and development of pharmaceutical products for the treatment of cancer and cancer-related diseases. It offers the following clinical stage product candidates: Mangoral, a liver imaging drug being developed for detection and localization of potential liver metastases; and Oncoral, a tablet-based formulation of the chemotherapeutic agent irinotecan, intended for the treatment of advanced gastric cancer. The company was founded on May 17, 1999, and is headquartered in Malmö, Sweden.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

ACE news



Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ACE is 2.600 SEK — it has decreased by −2.02% in the past 24 hours. Watch ASCELIA PHARMA AB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange ASCELIA PHARMA AB stocks are traded under the ticker ACE.
ACE stock has risen by 3.70% compared to the previous week, the month change is a 20.59% rise, over the last year ASCELIA PHARMA AB has showed a −9.41% decrease.
We've gathered analysts' opinions on ASCELIA PHARMA AB future price: according to them, ACE price has a max estimate of 10.00 SEK and a min estimate of 10.00 SEK. Watch ACE chart and read a more detailed ASCELIA PHARMA AB stock forecast: see what analysts think of ASCELIA PHARMA AB and suggest that you do with its stocks.
ACE reached its all-time high on Dec 16, 2020 with the price of 66.700 SEK, and its all-time low was 2.000 SEK and was reached on Sep 13, 2024. View more price dynamics on ACE chart.
See other stocks reaching their highest and lowest prices.
ACE stock is 8.43% volatile and has beta coefficient of 0.56. Track ASCELIA PHARMA AB stock price on the chart and check out the list of the most volatile stocks — is ASCELIA PHARMA AB there?
Today ASCELIA PHARMA AB has the market capitalization of ‪256.05 M‬, it has increased by 4.51% over the last week.
Yes, you can track ASCELIA PHARMA AB financials in yearly and quarterly reports right on TradingView.
ASCELIA PHARMA AB is going to release the next earnings report on Feb 7, 2025. Keep track of upcoming events with our Earnings Calendar.
ACE earnings for the last quarter are −0.14 SEK per share, whereas the estimation was −0.14 SEK resulting in a 0.00% surprise. The estimated earnings for the next quarter are −0.14 SEK per share. See more details about ASCELIA PHARMA AB earnings.
ASCELIA PHARMA AB revenue for the last quarter amounts to 0.00 SEK, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ACE net income for the last quarter is ‪−21.73 M‬ SEK, while the quarter before that showed ‪−13.27 M‬ SEK of net income which accounts for −63.76% change. Track more ASCELIA PHARMA AB financial stats to get the full picture.
No, ACE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 13.00 employees. See our rating of the largest employees — is ASCELIA PHARMA AB on this list?
Like other stocks, ACE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ASCELIA PHARMA AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ASCELIA PHARMA AB technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ASCELIA PHARMA AB stock shows the sell signal. See more of ASCELIA PHARMA AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.